Top

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Authors: Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Real-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in hormone receptor positive and human epidermal growth factor 2 receptor negative (HR+/HER2-) metastatic breast cancer (MBC) patients treated with Palbociclib in the northwest of China.

Methods

HR+/HER2- MBC patients who received Palbociclib in 8 centers from July 2017 to September 2019 were retrospectively included in this study. Real-world objective response rate (ORR), progression-free survival (PFS) and safety profiles were analyzed. The survival curves were plotted by the Kaplan-Meier method to analyze PFS, which was verified by the log-rank test.

Results

In total, 211 women were eligible for the analysis. A total of 85 patients (40.3%), 78 (37.0%), and 48 (22.7%) received Palbociclib in the first-, second-, third- or later-line setting, respectively. 46 patients achieved partial response and 145 patients experienced stable disease, with an ORR of 21.8% and a disease control rate of 90.5%. Following a median follow-up period of 14.2 months, the median PFS was 12.2 months (95% confidence interval, 10.1-14.3 m), and the median overall survival was not reached. Early Palbociclib initiation, sensitivity or acquired resistance to endocrine therapy, estrogen receptor and progesterone receptor double positivity, less than 3 metastatic sites, without visceral metastasis, bone metastasis only, without prior chemotherapy or endocrine therapy were associated with a prolonged PFS in MBC (All P < 0.05). The most common grade 3 or 4 adverse events (AE) was neutropenia (36.5%), and the most common nonhematologic AE was fatigue (10.9%). No patient experienced AE leading to treatment discontinuation.

Conclusion

Palbociclib plus endocrine therapy exhibited favorable effectiveness and manageable toxicities in the real-world setting, supporting their use in Chinese patients with HR+/HER2 − MBC.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA: a cancer journal for clinicians 2021, 71(1):7–33. https://doi.org/10.3322/caac.21654

Waks AG, Winer EP. Breast Cancer Treatment: a review. JAMA. 2019;321(3):288–300.CrossRef

Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast Cancer. Cancer Cell. 2020;37(4):496–513. https://doi.org/10.1001/jama.2018.19323.CrossRef

Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast Cancer: a review of preclinical and clinical data. Clin Breast Cancer. 2016;16(1):8–17. https://doi.org/10.1016/j.clbc.2015.07.005.CrossRef

Luftner D, Fasching PA, Haidinger R, Harbeck N, Jackisch C, Muller V, Schumacher-Wulf E, Thomssen C, Untch M, Wurstlein R. ABC6 Consensus: Assessment by a group of german experts. Breast Care (Basel). 2022;17(1):90–100. https://doi.org/10.1159/000522068.CrossRef

Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2020;18(4):452–78. https://doi.org/10.6004/jnccn.2020.0016.CrossRef

Owsley J, Jimeno A, Diamond JR. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer. Drugs of today (Barcelona, Spain: 1998) 2016, 52(2):119–129. https://doi.org/10.1358/dot.2016.52.2.2440528

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39. https://doi.org/10.1016/s1470-2045(15)00613-0.CrossRef

Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, et al. Palbociclib Plus Letrozole as First-Line therapy in postmenopausal asian women with metastatic breast Cancer: results from the Phase III, Randomized PALOMA-2 study. J global Oncol. 2019;5:1–19. https://doi.org/10.1200/jgo.18.00173.CrossRef

10.

Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, et al. Efficacy and safety of Palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast cancer research: BCR. 2016;18(1):67. https://doi.org/10.1186/s13058-016-0721-5.CrossRef

11.

Iwata H, Im SA, Masuda N, Im YH, Inoue K, Rai Y, Nakamura R, Kim JH, Hoffman JT, Zhang K, et al. PALOMA-3: phase III trial of Fulvestrant with or without Palbociclib in Premenopausal and Postmenopausal Women with hormone Receptor-Positive, human epidermal growth factor receptor 2-Negative metastatic breast Cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients. J global Oncol. 2017;3(4):289–303. https://doi.org/10.1200/jgo.2016.008318.CrossRef

12.

Bui TBV, Burgers DM, Agterof MJ, van de Garde EM. Real-world effectiveness of Palbociclib Versus Clinical Trial results in patients with Advanced/Metastatic breast Cancer that progressed on previous endocrine therapy. Breast Cancer (Auckl). 2019;13:1178223418823238. https://doi.org/10.1177/1178223418823238.CrossRef

13.

Edman Kessler L, Wiklander O, Hamberg E, Bergh J, Foukakis T, Matikas A. Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta Oncol. 2020;59(11):1382–7. https://doi.org/10.1080/0284186X.2020.1804613.CrossRef

14.

Wilkie J, Schickli MA, Berger MJ, Lustberg M, Reinbolt R, Noonan A, Ramaswamy B, Sardesai S, VanDeusen J, Wesolowski R, et al. Progression-free survival for real-world use of Palbociclib in hormone receptor-positive metastatic breast Cancer. Clin Breast Cancer. 2020;20(1):33–40. https://doi.org/10.1016/j.clbc.2019.06.010.CrossRef

15.

Liu C, Li T, Tao Z, Cao J, Wang L, Zhang J, Wang B, Hu X. Clinical outcomes of 130 patients with hormone receptor-positive and human epidermal growth factor receptor 2-Negative metastatic breast Cancer treated with Palbociclib plus Endocrine Therapy and subsequent therapy: a real-world Single-Center Retrospective Study in China. Med Sci Monit. 2020;26:e927187. https://doi.org/10.12659/MSM.927187.CrossRef

16.

Lee J, Park HS, Won HS, Yang JH, Lee HY, Woo IS, Shin K, Hong JH, Yang YJ, Chun SH, et al. Real-world Clinical Data of Palbociclib in Asian metastatic breast Cancer patients: experiences from eight institutions. Cancer Res Treat. 2021;53(2):409–23. https://doi.org/10.4143/crt.2020.451.CrossRef

17.

Odan N, Kikawa Y, Matsumoto H, Minohata J, Suwa H, Hashimoto T, Okuno T, Miyashita M, Saito M, Yamagami K, et al. Real-world outcomes of treating advanced breast Cancer patients with Palbociclib: a Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 study. Breast Cancer (Auckl). 2020;14:1178223420983843. https://doi.org/10.1177/1178223420983843.CrossRef

18.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. Breast Cancer-major changes in the american Joint Committee on Cancer eighth edition cancer staging manual. Cancer J Clin. 2017;67(4):290–303. https://doi.org/10.3322/caac.21393.CrossRef

19.

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/jco.19.02309.CrossRef

20.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused Update. Arch Pathol Lab Med. 2018;142(11):1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.CrossRef

21.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, et al. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience. J Cell Physiol. 2019;234(6):7708–17. https://doi.org/10.1002/jcp.27832.CrossRef

22.

Manso L, Hernando C, Galan M, Oliveira M, Cabrera MA, Bratos R, Rodriguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, et al. Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020;54:286–92. https://doi.org/10.1016/j.breast.2020.11.005.CrossRef

23.

DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, et al. Comparative effectiveness of first-line Palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021;23(1):37. https://doi.org/10.1186/s13058-021-01409-8.CrossRef

24.

Junji Lin* L. McRoy2, Maxine D Fisher1,Nan Hu1, Cralen Davis1, Debanjali Mitra2, Mark S Walke: Treatment patterns and clinical outcomes of Palbociclib-based therapy received in US community oncology practices. 2020. https://doi.org/10.2217/fon-2020-0744

25.

Mycock K, Zhan L, Taylor-Stokes G, Milligan G, Mitra D. Real-world palbociclib use in HR+/HER2- advanced breast Cancer in Canada: the IRIS Study. Curr Oncol. 2021;28(1):678–88. https://doi.org/10.3390/curroncol28010066.CrossRef

26.

John Waller PSI, Debanjali Mitra MBA, MA2, Katie, Mycock. MChem1; Gavin Taylor-Stokes, MBA1; Gary Milligan1; Lin Zhan, MS2; and: Real world treatment patterns and clinical outcomes associated with Palbociclib combination therapy in Argentina Results from the IRIS study. 2019. https://doi.org/10.1200/jgo.18.00239

27.

Varella L, Eziokwu AS, Jia X, Kruse M, Moore HCF, Budd GT, Abraham J, Montero AJ. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with Palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019;176(2):429–34. https://doi.org/10.1007/s10549-019-05176-1.CrossRef

28.

Kova CA, Matos E, Kuhar CG, Caks M, Ovcaricek T, Mencinger M, Humar M, Borstnar S. Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting. Cancer Treat Res Commun. 2020;25:100201. https://doi.org/10.1016/j.ctarc.2020.100201.CrossRef

29.

Palumbo R, Torrisi R, Sottotetti F, Presti D, Rita Gambaro A, Collovà E, Ferzi A, Agostinetto E, Maria Teragni C, Saltalamacchia G, et al. Patterns of treatment and outcome of Palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre italian study. Therapeutic Adv Med Oncol. 2021;13. https://doi.org/10.1177/1758835920987651.

30.

Yuan Y, Zhang S, Yan M, Yin Y, Song Y, Jiang Z. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study. Annals of translational medicine. 2021;9(10):831. https://doi.org/10.21037/atm-20-8252.CrossRef

31.

Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, et al. Long-term pooled Safety Analysis of Palbociclib in Combination with endocrine therapy for hormone Receptor-Positive/Human epidermal growth factor receptor 2-Negative advanced breast Cancer: updated analysis with up to 5 years of Follow-Up. Oncologist. 2021;26(5):e749–55. https://doi.org/10.1002/onco.13684.CrossRef

32.

Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69(3):313–7. https://doi.org/10.1007/s13304-017-0424-1.CrossRef

33.

Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, Andre F, Harbeck N, et al. Palbociclib Combined with Fulvestrant in Premenopausal women with advanced breast Cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017;22(9):1028–38. https://doi.org/10.1634/theoncologist.2017-0072.CrossRef

34.

Xu B, Zhang, Qingyuan, Zhang P, Tong Z, Sun T, Li W, Ouyang Q, Cheng XHuY. Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial. Ann Oncol. 2022;33(suppl7):808–S869. https://doi.org/10.1016/annonc/annonc1089.CrossRef

35.

Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for Endocrine-Sensitive, hormone Receptor-Positive, ERBB2-Negative advanced breast Cancer: a Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–9. https://doi.org/10.1001/jamaoncol.2021.4301.CrossRef

36.

Albanell J, Martínez MT, Ramos M, O’Connor M, de la Cruz-Merino L, Santaballa A, Martínez-JN, Moreno F, Fernández I, Alarcón J, et al. Randomized phase II study of fulvestrant plus Palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur J Cancer. 2022;161:26–37. https://doi.org/10.1016/j.ejca.2021.11.010.CrossRef

37.

Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Annals of oncology: official journal of the European Society for Medical Oncology. 2021;32(4):488–99. https://doi.org/10.1016/j.annonc.2020.12.013.CrossRef

38.

Lee J, Im SA, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park YH. Implications of tamoxifen resistance in Palbociclib Efficacy for patients with hormone Receptor-Positive, HER2-Negative metastatic breast Cancer: subgroup analyses of KCSG-BR15-10 (YoungPEARL). Cancer Res Treat. 2021;53(3):695–702. https://doi.org/10.4143/crt.2020.1246.CrossRef

39.

Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, et al. The genomic Landscape of intrinsic and Acquired Resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast Cancer. Cancer Discov. 2020;10(8):1174–93. https://doi.org/10.1158/2159-8290.Cd-19-1390.CrossRef

40.

Palleschi M, Maltoni R, Ravaioli S, Vagheggini A, Mannozzi F, Fanini F, Pirini F, Tumedei MM, Barzotti E, Cecconetto L, et al. Ki67 and PR in patients treated with CDK4/6 inhibitors: a real-world experience. Diagnostics (Basel Switzerland). 2020;10(8). https://doi.org/10.3390/diagnostics10080573.

41.

Shao X, Zheng Y, Cao W, Shen X, Li G, Chen J, Huang Y, Huang P, Shi L, Ye W, et al. Ki67 and progesterone receptor status predicts sensitivity to Palbociclib: a real-world study. Annals of translational medicine. 2021;9(8):707. https://doi.org/10.21037/atm-21-1340.CrossRef

42.

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, et al. Overall survival of CDK4/6-Inhibitor-based treatments in clinically relevant subgroups of metastatic breast Cancer: systematic review and Meta-analysis. J Natl Cancer Inst. 2020;112(11):1089–97. https://doi.org/10.1093/jnci/djaa071.CrossRef

Title: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Authors: Jiao Yang
Bing Zhao
Xiaoling Ling
Donghui Li
Jiuda Zhao
Yonggang Lv
Guangxi Wang
Xinlan Liu
Nanlin Li
Jin Yang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10568-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma

Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study

Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma

Deep learning-based multifeature integration robustly predicts central lymph node metastasis in papillary thyroid cancer

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer